Cargando…
Targeting Melanin in Melanoma with Radionuclide Therapy
Nearly 100,000 individuals are expected to be diagnosed with melanoma in the United States in 2022. Treatment options for late-stage metastatic disease up until the 2010s were few and offered only slight improvement to the overall survival. The introduction of B-RAF inhibitors and anti-CTLA4 and ant...
Autores principales: | Allen, Kevin J. H., Malo, Mackenzie E., Jiao, Rubin, Dadachova, Ekaterina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455397/ https://www.ncbi.nlm.nih.gov/pubmed/36076924 http://dx.doi.org/10.3390/ijms23179520 |
Ejemplares similares
-
Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma
por: Malo, Mackenzie E., et al.
Publicado: (2020) -
A Theranostic Approach to Imaging and Treating Melanoma with (203)Pb/(212)Pb-Labeled Antibody Targeting Melanin
por: Jiao, Rubin, et al.
Publicado: (2023) -
Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium
por: Allen, Kevin J. H., et al.
Publicado: (2019) -
Targeted Radionuclide Therapy of Cancer and Infections
por: van der Wal, Bart C. H., et al.
Publicado: (2023) -
Biodistribution of a Radiolabeled Antibody in Mice as an Approach to Evaluating Antibody Pharmacokinetics
por: Allen, Kevin J. H., et al.
Publicado: (2018)